Atlas Trials

Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

Clinical trial NCT06245291 · WITHDRAWN

Trial details

NCT number
NCT06245291
Sponsor
Arbutus Biopharma Corporation
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatitis B, Chronic
Start date
2024-05-01
Primary completion
2024-08-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.